That is below the 30% rate reported at an interim stage of the study at the International Liver Congress earlier this year, but still sufficient for GSK to take the drug forward into a phase 3 ...
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...
Harvey Jones has something to celebrate after a positive set of results boosted the GSK share price after a disappointing ... solid but not spectacular at 3.9%.Glaxo’s full-year 2024 dividend ...
The GSK (LSE: GSK) share price was causing me a lot of aggro ... The trailing dividend yield‘s solid but not spectacular at 3.9%.Glaxo’s full-year 2024 dividend will be 61p. The board’s forecasting ...
GSK has news on that front today, as well, reporting that the phase 2/3 COSTAR trial of Jemperli with experimental TIM-3 antagonist cobolimab will move into the phase 3 stage on the advice of its ...
Pharmaceutical giant GSK climbed 7.6% after announcing a £2 billion share buyback, lifting its long-term sales target to almost $50 billion. Gold miners also saw a 3.6% increase, with Fresnillo ...
Teva Pharmaceutical Industries Ltd. ADR-2.66% $19.77B ...
After hours: February 7 at 6:55:00 PM EST Loading Chart for GSK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback